Zeteo Biomedical receives new EU and US patents for its drug delivery technologies
ZTech-L and ZTech-P, as part of the ZTech portfolio, supports administering therapeutics in both liquid and dry powder formulations
(Image credit: ©angellodeco/AdobeStock)
Zeteo Biomedical recently received new patents for its drug delivery technologies ZTech portfolio in both the United States and European Union.1 The first patent is titled, “Cartridge Devices for Administration of a Medicament” (US Patent No. 12329949), and the second patent is titled, “Hand-Operated Device for Administration of a Medicament” (EU Patent No. 3946526).
The patents allow Zeteo to further expand and strengthen its ZTech drug delivery platform portfolio, advancing the technologies of ZTech-L and ZTech-P, both of which include single-use disposable and multi-dose, cartridge-reloadable handheld devices.
“We are seeing increasing global demand for metered-dose nasal, ophthalmic and sublingual delivery devices that are compact, intuitive and suitable for self-administration,” said Timothy Sullivan, chief executive officer of Zeteo Biomedical.
“A unique feature that sets our device technology apart is its ability to function reliably in any physical orientation, making it ideal for medication delivery in both terrestrial and space-based microgravity environments. This capability opens exciting new frontiers for Zeteo including applications in space-based healthcare.”
The technologies of ZTech-L and ZTech-P support administering therapeutics in both liquid and dry powder formulations, including vaccines, biologics and specialty drugs. Zeteo noted in a press release that nasal delivery is particularly a highly effective, non-invasive alternative for the treatment of conditions like pain, emesis, seizures, neurodegenerative and autoimmune disorders, infectious diseases and bioterror threats.
Based in Texas, Zeteo’s platform technologies aim to meet the ever-evolving demands of healthcare markets globally, “delivering precision, performance, and portability for the next-generation of therapeutic drug/device combination products,” a press release said. Zeteo’s technology focuses on patient-friendly design, which can improve treatment adherence and medical outcomes.
Reference:
1. Sullivan T. Zeteo Biomedical Secures Global Patents for Nasal and Ophthalmic Drug Delivery Device Innovations. Zeteo Biomedical. Published June 11, 2025. Accessed June 11, 2025. https://zeteobiomed.com/2025/06/zeteo-biomedical-secures-global-patents-for-nasal-and-ophthalmic-drug-delivery-device-innovations/
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
